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Abstract
Background—We evaluated the American College of Surgeon’s National Cancer Data Base 
(NCDB) to describe current hospital-based epidemiologic frequency, survival, and patterns of care 
of pediatric medulloblastoma.
Methods—We analyzed NCDB 1998–2011 data on medulloblastoma for children ages 0–19 
years using logistic and poisson regression, Kaplan-Meier survival estimates, and Cox 
proportional hazards models.
Results—3,647 cases of medulloblastoma in those aged 0–19 years were identified. 
Chemotherapy was received by 79% and 74% received radiation, with 65% receiving both 
therapies. Those who received radiation were more likely to be older than four, while those who 
received chemotherapy were more likely to be age four and younger. Variables associated with 
receipt of neither radiation nor chemotherapy included age at diagnosis of <1 year, female gender, 
being of race other than black or white, having no insurance, and living in a residential area with a 
low level of high school graduates. Better overall survival was observed as age at diagnosis 
increased, in females, and having received radiation. Compared to medulloblastoma, NOS, better 
survival was observed for those with demoplastic medulloblastoma, with worse survival in those 
with large cell medulloblastoma.
Conclusion—Majority received multi- disciplinary therapy and radiation had the greatest effect 
on survival. Ages four and under were most likely to receive chemotherapy and least likely to 
receive radiation. Suboptimal treatment included 17.8% that did not receive chemotherapy, of 
which 11.8% received neither chemotherapy nor radiation. Disparities associated with medical 
access were characteristics for not receiving standard treatment, which resulted in poor outcome.
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Introduction
Medulloblastoma is the most common brain neoplasm in the pediatric population [1,2]. A 
disease of the young, 70% of cases affect children 16 years or younger, with the peak 
incidence occurring at age seven [1–3]. A malignant tumor, classified as World Health 
Organization (WHO) grade IV, medulloblastoma has a 70% survival at five years from 
diagnosis compared to 30% survival in the 1960s [4]. The improved survival has been 
attributed to inclusion of radiation therapy, advances in imaging, and improvements in 
supportive care [1,5,6]. More recent advances in survival, however, have lagged compared to 
other common pediatric cancers [7].
Medulloblastoma is an embryonal tumor with neuronal differentiation arising from the 
cerebellum with an inherent tendency to spread along the neuro-axis [8,9]. This embryonal 
group includes primitive neuroectodermal tumors, atypical teratoid/rhabdoid tumors, and 
embryonal tumor with multilayered rosettes [10]. WHO classifies medulloblastoma into four 
subtypes: desmoplastic/nodular, anaplastic, large cell, and medulloblastoma with extensive 
nodularity [9]. Recent genomic characterization has identified four intrinsic subtypes, Wnt, 
Shh, group 3, and group 4 [11–13]. Treament is based on risk stratification including age, 
extent of surgical resection, presence of metastatic disease, and large cell histology.
Treatment for medulloblastoma is based on multi-disciplinary therapy with maximal safe 
resection surgery, radiation when tolerable, and multi-agent systemic chemotherapy. Current 
concerns include the use of radiation therapy in very young children (less than three years) 
and methods to limit the exposure of radiation to all children, such as proton beam, focal 
radiation, or lower dose of radiation [5,4,14]. Investigations on quality of life following 
treatment have also been of special interest and include neurocognitive decline, impairment 
of growth and endocrine function, hearing loss, and secondary neoplasms [15,16]. There is 
also a role in refractory cases for high dose chemotherapy with autologous stem cell 
transplantation [17,18]. Recent inclusion of targeted agents is being considered for specific 
molecular subtypes [19,20].
As a disease affecting children and young adults, inadequate treatment can result in death 
from a potentially curative disease [21]. Our analysis of the American College of Surgeons 
National Cancer Data Base (NCDB) describes current hospital-based epidemiologic 
frequency, patterns of care, and survival for pediatric medulloblastoma.
Methods
The NCDB, a joint program of the American College of Surgeons and the American Cancer 
Society, contains cancer patient demographics, tumor identification characteristics, 
treatment, and outcomes data. NCDB captures nearly 75% of all newly diagnosed cancer 
cases in the United States from over 1,450 Commission on Cancer accredited hospitals in 49 
states. Data reported to the NCDB are retrospective in nature and are in compliance with the 
privacy requirements of the Health Insurance Portability and Accountability Act of 1996 as 
reported in the Standards for Privacy of Individually Identifiable Health Information; Final 
Rule (45 CFR Parts 160 and 164).
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A total of 3,647 patients ages 0–19 years diagnosed with medulloblastoma, defined as 
International Classification of Diseases for Oncology (ICD-O-3) histology/behavior codes 
9470/3, 9471/3 and 9474/3 and limited to primary tumor sites C71.0–C71.9, were identified 
from the NCDB hospital-based cancer registry for years 1998–2011. Fourteen cases 
included in the analyses were coded as a second or unknown primary. Data were abstracted 
according to the Facility Oncology Registry Data Standards (FORDS) manual. Follow-up of 
cases is pursued every 5 years following the initial year of diagnosis (i.e. for a case 
diagnosed in 1990, follow-up would be done in 1995, 2000, etc. until death or lost to follow-
up).
Descriptive statistics were reported overall, and stratified by age group (<5 years and 5–19 
years). Primary site was stratified into the following groups: brain stem (C71.7), cerebellum 
(C71.6), ventricle (C71.5), and others (C71.0–71.4 and 71.8–71.9). If the patient received 
any therapy (radiation, chemotherapy, and/or surgery) during their first course of treatment, 
they were classified as “yes” for that particular treatment. The insurance variable identified 
the patient’s primary insurance carrier at the time of diagnosis and/or treatment. Income and 
education were defined as the median household income and the number of adults who did 
not graduate from high school, respectively, in the patient’s residential zip code at the time 
of diagnosis as derived from the 2000 US Census data.[22] Region was defined by 
comparing the patient’s residential state and county Federal Information Processing 
Standard (FIPS) code at diagnosis to the 2003 Rural-Urban Continuum Codes as developed 
by the US Department of Agriculture Economic Research Service.[22] For our purposes, 
metro was defined as counties with a population of 250,000 or more; urban had a population 
of 2,500 to less than 250,000; rural had a population of less than 2,500.
Descriptive demographics were presented using frequency for categorical variables, with 
differences between groups assessed using Chi-Square tests. Multivariable logistic 
regression was performed to analyze the factors that may influence receipt of a specific 
treatment (e.g. radiation treatment, chemotherapy, and neither radiation or chemotherapy). 
Variables which were statistically significant in any of the full models listed above were 
included in all of the final models, and model selection was performed to identify critical 
variables with lower values of Akaike Information Criteria (AIC) suggesting better model 
fit. Because of the large number of patients with unknown tumor size, this variable was not 
included in any of the logistic regression models. Due to missing covariates, 484 cases were 
excluded from the radiation model, 562 cases were excluded from the chemotherapy model, 
and 647 cases were excluded from the neither treatment model. Poisson regression was 
employed to assess univariate changes in counts over time, by histology, and by treatment 
received.
Survival was defined as time from diagnosis until death due to all causes. Data for survival 
analysis in this paper were only available from 1998 to 2006 due to the 5-year NCDB lag in 
collecting and reporting survival/follow-up data (n=2,358). Kaplan-Meier estimates of 
overall survival were calculated. Cox proportional hazards models were employed to assess 
the risk of mortality according to receiving both radiation and chemotherapy treatments 
while adjusting for other potential risk factors. These hazard ratios should be interpreted as 
the average risk of death over the entire time period presented. Due to missing covariate 
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data, 199 cases were excluded from the estimation of the hazard ratios. The level of 
statistical significance was set at 0.05 for all tests conducted, and all analyses were 
performed with SAS software version 9.4 for Microsoft Windows on ×64 (SAS Statistical 
Institute, Cary, NC).
Results
A total of 3,647 children aged 0–19 years with medulloblastoma were included in NCDB 
between 1998 and 2011 (Table 1). Almost one-third of these were in children less than 5 
years of age. The frequency in males (63%) was higher than in females, while whites 
accounted for 81% of cases. Medulloblastoma, NOS (87%) was the most frequently 
diagnosed tumor histology, followed by desmoplastic medulloblastoma (9%) and large cell 
medulloblastoma (4%). Interestingly, over time, the frequency of a large cell or demoplastic 
medulloblastoma diagnosis significantly increased at a rate of 10% (p=0.001) and 3% 
(p=0.03) per year, respectively, while the less specific diagnosis of medulloblastoma, NOS 
significantly decreased by a rate of 2% per year (p=0.0003). Only 4% of patients with 
medulloblastoma reported no insurance, and only 2% of patients lived in a rural area at the 
time of diagnosis. At diagnosis, a greater frequency of patients were living in zip codes with 
the highest categorical median income of $46,000 + (37%) and with the lowest percentage 
of adults who did not finish high school (32%).
The vast majority (over 96%) of patients with medulloblastoma received surgery. The 
frequency of those who received chemotherapy was 79% and those who received radiation 
therapy was 74%, with 65% of all patients receiving both therapies (Table 1). Over the 
1998–2011 diagnosis period, the frequency of patients receiving radiation only decreased at 
a statistically significantly rate of 4% per year (p=0.005; Fig. 1). There were no changes 
over time in the frequencies of patients receiving both chemotherapy and radiation, 
chemotherapy only, or neither chemotherapy nor radiation (p>0.05 for all). When stratified 
by age, children aged 0–4 years were more likely than those aged 5–19 years to be Hispanic 
(p=0.01), of ‘other’ race (p=0.02), and live in an urban area (p=0.03). Children 0–4 years 
were also more likely to be on Medicaid and less likely to have private insurance 
(p<0.0001). Medulloblastoma, NOS was more frequently diagnosed in children aged 5–19 
years (89.7% vs 80.1%), while children aged 0–4 years had a higher frequency of diagnosis 
of desmoplastic medulloblastoma (14.9% vs 7.1%) and large cell medulloblastoma (5.0% vs 
3.2%) than older children (p<0.0001). Children aged 5–19 years were more likely than those 
aged 0–4 years to have received radiation therapy (84.4% vs 49.7%, p<0.0001), but were 
less likely to have received chemotherapy (77.4% vs 82.1%, p=0.004). By treatment 
combination category, children aged 5–19 years were more likely to have received both 
radiation and chemotherapy (73.4% vs 45.1%) or radiation only (11.0% vs 4.6%), but were 
less likely to have received chemotherapy only (4.0% vs 37.0%) or neither therapy (11.3% 
vs 13.0%) than children aged 0–4 years (p<0.001).
To determine the characteristics which led to receiving radiation therapy, chemotherapy, or 
neither, logistic regression models were created (Table 2). Compared with uninsured 
patients, private, Medicaid, or Medicare insured patients were 72%, 71%, or more than twice 
as likely to receive radiation treatment, respectively. Conversely, those under the age of 5, 
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females, and those whose zip code corresponded to the lowest quartile of high school 
graduates were statistically significantly less likely to receive radiation therapy. Similarly, 
patients who had any type of insurance (private, Medicaid, or Medicare) were more than 
twice as likely to receive chemotherapy than those with no insurance. Children in the 1–4 
and 5–9 year age groups were also 62% and 28% more likely to receive chemotherapy than 
those in the 10–19 year age group. While children less than 1 year of age were also 39% 
more likely to receive chemotherapy than the oldest age group, this difference was not 
statistically significant, likely due to smaller counts. Non-whites were less likely to receive 
chemotherapy, as were those whose zip code corresponded to the lowest quartile of high 
school graduates. Those who received neither radiation therapy nor chemotherapy in the first 
round of treatment were more likely to be less than 1 year of age (69%), female (35%), of 
‘other’ race (74%), and live in a zip code with the lowest percentage of high school 
graduates (59%). Conversely, those with any type of insurance, whether private, Medicaid, 
or Medicare, were less likely to have received neither radiation nor chemotherapy.
Overall five-year survival was 72.6% [95% Confidence Interval (CI): 70.6–74.5] in children 
aged 0–19 years who were diagnosed during the years 1998 through 2006 (n=2,358). Cox 
proportional hazard models, including variables which showed significance after model 
selection, identified several factors that influenced survival rates (Table 3). Compared to 
those aged 10–19 years (Fig. 2a and Table 3), survival was statistically significantly lower in 
all younger age groups, with survival being lowest in the youngest age group (aged <1 year) 
at diagnosis. Five-year survival rates were: 47.4% (<1 year), 64.5% (ages 1–4), 74.2% (ages 
5–9), 81.5% (ages 10–19). Females had statistically significantly better survival than males, 
and blacks had statistically significantly better survival than whites. Those who lived in a zip 
code with median household incomes less than $30,000 and $35,000–$45,999 both had 
survival rates that were worse than those with median household incomes in the highest 
quartile. Children diagnosed with desmoplastic medulloblastoma had one-third better 
survival, while those with large cell medulloblastoma had 2 times worse survival, than those 
diagnosed with medulloblastoma, NOS.
With regard to treatment, patients who received radiation alone in the first course of 
treatment had comparable survival rates to those who received both radiation and 
chemotherapy (Table 3). Alternatively, those who received chemotherapy alone or neither 
radiation nor chemotherapy had statistically significantly worse survival than those who 
received both therapies. In post-hoc analyses comparing the survival curves for the four 
different treatment combinations (both radiation and chemotherapy, radiation alone, 
chemotherapy alone, and neither; Fig. 2b) survival for those receiving both radiation and 
chemotherapy and those who received only radiation in the first round of treatment were not 
significantly different from each other (Hazard Ratio:0.93, 95% CI:0.69–1.25). Similarly, 
survival for those who received only chemotherapy was not significantly different from 
those who received neither radiation nor chemotherapy (0.86, 0.65–1.15). Those who 
received both therapies or radiation only had significantly better survival than those who 
received chemotherapy alone or neither therapies in the first round of treatment (both vs 
chemotherapy only: 0.61, 0.49–0.77; both vs neither: 0.53, 0.42–0.67; chemotherapy only vs 
radiation only: 1.52, 1.07–2.16; neither vs radiation only: 1.76, 1.24–2.49).
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Discussion
Medulloblastoma is a common and curable pediatric cancer. Optimal treatment requires 
advanced care in specialized centers. NCDB is the largest clinical cancer registry and 
analysis is important to assess what types of therapeutic options have been used and their 
expected outcomes. The most prominent finding in our investigation is the frequency that 
patients do not receive multi- disciplinary therapy, specifically radiation and/or 
chemotherapy. Patients who do not receive radiation have significantly worse outcomes. The 
patients most likely to not receive radiation are younger, female, or have suspected 
socioeconomic impediments that limit access to care.
In general we reaffirm the survival benefit of radiation, either as monotherapy or combined 
with chemotherapy [5,4]. Our results also demonstrate that chemotherapy alone is inferior to 
radiation, which is consistent with the findings of most prospective treatment trials for 
medulloblastomas [23,5,4,14,24–27]. The combined use of radiation and chemotherapy, 
which is the established care for children greater than three years old, however, did not 
provide statistical benefit compared to radiation alone, although there was a trend towards 
benefit. The reason for this lack of combined benefit could be that chemotherapy overlaps 
with the clinical benefit from radiation or the sequence of therapy has yet to be optimized or 
that the benefits and/or harm are restricted to specific genetic subtypes and become diluted 
in our analysis.
Radiation has demonstrated a dose dependent effect on outcomes in clinical trials 
[5,4,24,25]. Acknowledging that radiation is usually avoided in children younger than age 
three or four due to concerns of treatment related long-term cognitive effects, we sought to 
identify socio-demographic factors that may prevent patients from receiving radiation 
treatments. We found as expected that the under five age group was significantly less likely 
to receive radiation. We also found female gender, lack of insurance, and living in areas with 
lower education were associated with not receiving radiation. No statistically significant 
differences were noted by race, although we observe a trend toward increased radiation 
treatments among blacks or being of race other than black or white. We also found, as 
demonstrated in clinical trials, the superior benefit of radiation for initial treatment following 
surgery versus initial use of chemotherapy [23,27].
Chemotherapy without radiation is usually preferred for infants and toddlers under three or 
four years old [26]. This age group is known to present more frequently with disseminated 
disease and have inferior outcomes compared to older children [5,4]. Our analysis 
demonstrates that this early age group is most likely to receive chemotherapy and least likely 
to receive radiation, in keeping with the literature. We also found that overall 17.8% of 
children and adolescents did not receive chemotherapy during first-line treatment. This was 
unexpected as chemotherapy is incorporated as standard of care for all ages in 
medulloblastoma. In our analysis we further identifed an unfortunate group that received 
neither radiation nor chemotherapy. This group was associated with infants less than one 
year old, female gender, lack of insurance, and living in areas with lower education. It is not 
clear from our data why a significant proportion of children are not receiving optimal 
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multimodal treatment and is a topic for further investigation. This is an opportunity to 
increase treatment and significantly improve survival.
Our results also confirmed previous clinical studies that report subtype dependent outcomes, 
specifically poorer outcomes are seen with large cell [5] and more favorable outcomes with 
desmoplastic [28,26]. These two subtypes, their relation to the recent molecular 
classification, and incorporation for prognosis and treatment are still evolving. Our analysis 
also demonstrates that the incidence of these subtypes, large cell and desmoplastic, are 
increasing, while the less specific medulloblastoma, NOS is decreasing. This is likely due to 
wider acceptance of subtype classification based on WHO criteria.
Although NCDB is considered nationally applicable, there are limitations in this data. Most 
pediatric patients will be referred to regional specialty centers, but true access to these 
centers is not known and this may affect the ability of patients to receive optimal care. 
Limits of current registry data include lack of information on the dose, volume, or treatment 
planning for radiation and chemotherapies. There are also concerns on the quality of registry 
data collected over long periods including changes in histologic classification, although in 
the time-period of our analysis classification of medulloblastomas has largely remained 
unchanged [29].
In summary we report patterns of care and outcomes for initial care of medulloblastoma 
using the largest hospital-based cancer database. Our evaluation reinforces the established 
benefits of treatment, specifically radiation. We found patterns of treatment based on age in 
keeping with the literature. Large cell and desmoplastic subtypes of medulloblastoma had 
outcome differences, which can be used prognostically in future treatment investigations. 
Finally female gender and disparities associated with access to care emerged as important 
characteristics for treatment and survival. For a curable cancer in children, it is critical to 
investigate this non-treatment group in detail.
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Fig. 1. 
Types of Treatment Received by Year of Diagnosis
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Fig. 2. 
a Overall Survival for Diagnosed Cases 1998–2006 by Age
b Overall Survival for Diagnosed Cases 1998–2006 by Treatment
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Table 3
Effects of selected characteristics on survival for children aged 0–19 years diagnosed with medulloblastoma, 
NCDB 1998–2006 (n=2,358).
Variable Hazard Ratio* 95% Confidence Interval p-value
Age Group
 <1 year old 3.06 2.07–4.53 <0.0001
 1–4 years old 1.81 1.44–2.27 <0.0001
 5–9 years old 1.34 1.08–1.66 0.01
 10–19 years old 1.00
Gender
 Male 1.00
 Female 0.79 0.67–0.94 0.01
Race
 White 1.00
 Black 0.71 0.53–0.94 0.02
 Others 0.72 0.48–1.09 0.12
Income
 < $30,000 1.39 1.10–1.75 0.01
 $30,000 – $34,999 1.00 0.78–1.27 0.98
 $35,000 – $45,999 1.28 1.05–1.55 0.01
 $46,000 + 1.00
Histology
 Medulloblastoma, NOS 1.00
 Desmoplastic Medulloblastoma 0.69 0.51–0.94 0.02
 Large Cell Medulloblastoma 2.61 1.76–3.89 <0.0001
Radiation & Chemotherapy
 Both 1.00
 Radiation Only 1.08 0.80–1.46 0.62
 Chemo Only 1.64 1.30–2.06 <0.0001
 Neither 1.89 1.50–2.38 <0.0001
*
199 subjects were excluded from the analyses due to missing data in covariates. Hazard Ratio adjusted for all variables listed above. Model was 
selected using Cox proportional hazards with backward selection and AIC values.
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